Insider Selling: Pharvaris (NASDAQ:PHVS) Insider Sells 300 Shares

Posted by George Bondi on Jun 23rd, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) insider Peng Lu sold 300 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $34.00, for a total value of $10,200.00. Following the sale, the insider owned 65,631 shares of the company’s stock, valued at approximately $2,231,454. This represents a 0.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Peng Lu also recently made the following trade(s):

On Wednesday, April 29th, Peng Lu sold 3,733 shares of Pharvaris stock. The stock was sold at an average price of $30.06, for a total value of $112,213.98.
On Thursday, April 30th, Peng Lu sold 15,000 shares of Pharvaris stock. The shares were sold at an average price of $30.24, for a total transaction of $453,600.00.
On Thursday, April 23rd, Peng Lu sold 100 shares of Pharvaris stock. The shares were sold at an average price of $30.03, for a total transaction of $3,003.00.
On Wednesday, April 22nd, Peng Lu sold 7,001 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,380.05.

Pharvaris Stock Up 0.6%

PHVS traded up $0.19 during trading on Tuesday, hitting $33.19. 326,665 shares of the company’s stock were exchanged, compared to its average volume of 243,931. The business’s 50 day moving average is $30.13 and its two-hundred day moving average is $27.82. Pharvaris N.V. has a fifty-two week low of $16.72 and a fifty-two week high of $34.41. The stock has a market cap of $2.17 billion, a P/E ratio of -10.44 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. On average, sell-side analysts forecast that Pharvaris N.V. will post -3.22 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on PHVS. Citizens Jmp cut their price target on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Wedbush increased their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating on shares of Pharvaris in a research report on Tuesday, June 16th. Finally, UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pharvaris presently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

Check Out Our Latest Research Report on PHVS

Hedge Funds Weigh In On Pharvaris

Several institutional investors have recently modified their holdings of PHVS. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Pharvaris by 30.6% during the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc lifted its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period. Amundi boosted its position in Pharvaris by 2,741,600.0% in the second quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after purchasing an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Pharvaris by 19.2% in the second quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after purchasing an additional 7,879 shares during the last quarter.

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.